Peripheral nerve repair biologics and processed nerve allograft maker
Axogen develops and commercializes technologies for peripheral nerve regeneration, including processed nerve allografts. Hiring is accelerating and skews toward manufacturing, backed by Tulip, Minitab and GMP compliance pressures that point to a production scale-up. Commercial effort centers on market development in OMF/head and neck, while a Microsoft-centric stack (Fabric, Power BI, Dynamics 365, Azure DevOps) anchors analytics and operations.
Notable leadership hires: Sales Director
Axogen is a publicly traded company founded in 2002 and headquartered in Alachua, Florida, with 201–500 employees. It focuses on the science, development and commercialization of products for peripheral nerve repair, spanning tissue engineering, biologics and nerve allografts, including applications in breast reconstruction. The company sells to surgeons and healthcare providers through a field sales and marketing organization. Its hiring is concentrated in the United States across manufacturing, sales, marketing, engineering and quality functions.
Axogen runs a Microsoft-heavy stack including Power BI, Microsoft Fabric, Azure, Azure DevOps and Dynamics 365, plus Tulip and Minitab for manufacturing, Veeva PromoMats and Veeva EDC, and Okta and Duo Security for identity.
Yes. Manufacturing is Axogen's largest hiring area, with additional openings in sales, marketing, engineering and quality, all based in the United States, and overall hiring velocity is accelerating.
Axogen is headquartered in Alachua, Florida, United States. It is a public company founded in 2002 with 201–500 employees.
Other companies in the same industry, closest in size
axogen's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.